Title :

Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort.

Author(s) :

Faiz, Sarah [Auteur]
Giovannelli, Jonathan [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Podevin, Celine [Auteur]
Jachiet, Marie [Auteur]
Bouaziz, Jean-David [Auteur]
Reguiai, Ziad [Auteur]
Nosbaum, Audrey [Auteur]
Lasek, Audrey [Auteur]
Ferrier Le Bouedec, Marie-Christine [Auteur]
Du Thanh, Aurelie [Auteur]
Raison-Peyron, Nadia [Auteur]
Tetart, Florence [Auteur]
Duval-Modeste, Anne-Benedicte [Auteur]
Misery, Laurent [Auteur]
Aubin, Francois [Auteur]
Dompmartin, Anne [Auteur]
Morice, Cecile [Auteur]
Droitcourt, Catherine [Auteur]
Soria, Angele [Auteur]
Arnault, Jean-Philippe [Auteur]
Delaunay, Juliette [Auteur]
Mahe, Emmanuel [Auteur]
Richard, Marie-Aleth [Auteur]
Schoeffler, Amelie [Auteur]
Lacour, Jean-Philippe [Auteur]
Begon, Edouard [Auteur]
Walter-Lepage, Amelie [Auteur]
Dillies, Anne-Sophie [Auteur]
Rappelle-Duruy, Sandrine [Auteur]
Barete, Stephane [Auteur]
Bellon, Nathalia [Auteur]
Beneton, Nathalie [Auteur]
Valois, Aude [Auteur]
Barbarot, Sebastien [Auteur]
Seneschal, Julien [Auteur]
Staumont-Salle, Delphine [Auteur]

Journal title :

Journal of the American Academy of Dermatology

Abbreviated title :

J. Am. Acad. Dermatol.

Publication date :

2019-02-27

ISSN :

1097-6787

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

BACKGROUND: Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials. OBJECTIVE: We sought to assess the effectiveness and safety of ...
Show more >BACKGROUND: Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials. OBJECTIVE: We sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort. METHODS: We included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up. RESULTS: We included 241 patients. The median ± interquartile range (IQR) follow-up time was 3.8 ± 3.7 months. A ≥75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a ≥75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD ± IQR, 25 ± 21 vs 56 ± 27.4, P < 10 and EASI ± IQR, 4.1 ± 6.8 vs 17.9 ± 15.4, P < 10 , respectively). Conjunctivitis was reported in 84 of 241 (38.2%) patients. The proportion with eosinophilia (>500 cells/mm ) during follow-up (57%) was higher than that at baseline (33.7%) (n = 172, P < 10 ). Dupilumab was stopped in 42 cases; 27 patients stopped because of AEs. CONCLUSIONS: No control group, missing data. CONCLUSIONS: This real-life study demonstrated a similar dupilumab effectiveness as that seen in clinical trials, but it also revealed a higher frequency of conjunctivitis and eosinophilia.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2019-10-22T07:44:56Z